Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a
multi-center, randomized, double-masked, placebo-controlled phase III clinical study. 237
patients with central retinal vein occlusion(CRVO) are expected to be enrolled in the study
and randomly assigned into the Conbercept ophthalmic injection treatment group or the control
group at a ratio of 2:1.